Novo Nordisk is a global healthcare company that discovers, develops, manufactures and delivers medicines and therapies for serious chronic diseases. Founded in 1923 and headquartered in Denmark, it employs approximately 67,000 people and operates affiliates in 80 countries, with sites in Belgium, Brazil, China, France, Italy, India, the United States and the United Kingdom. Its portfolio serves more than 46.5 million people worldwide.
The company's technical work spans pharmaceutical research and development, drug discovery and biologics manufacturing. Core therapeutic areas include diabetes and obesity, haemophilia, growth disorders and cardiovascular conditions. The company operates an integrated model covering the full chain from discovery and development to manufacturing and delivery, a structure that places engineering, data and process disciplines alongside laboratory science.
Scientific work at Novo Nordisk is oriented towards chronic disease, combining research with an understanding of patients' daily lives and an emphasis on expanding access to treatments. The company continues to pursue new scientific breakthroughs under CEO Maziar Mike Doustdar. Further information is available at https://novonordisk.com/.
